Clinical trial
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to…
NCT00005073 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00005073 |
|---|---|
| Title | Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms |
| Official title | A Randomized Double-Blind Placebo Controlled Phase III Trial Evaluating Zoledronate Plus Standard Therapy Versus Placebo Plus Standard Therapy in Patients With Recurrent Carcinoma of the Prostate Who Are Asymptomatic With Castrate Levels of Testosterone and Have Rising PSA Levels Without… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | zoledronic acid |
| Enrollment | 544 |
| Start date | Sep 1, 1999 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Jun 18, 2004 |
| Last update posted | May 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: